Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription 20.07.2026 5 Ann Hematol 1 Biochem Biophys Res Commun 1 Biochem Pharmacol 1 Blood 1 BMC Cancer 5 Bone Marrow Transplant 1 Br J Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 3 Eur J Haematol 3 Exp Hematol 2 Int J Hematol 1 J Clin Oncol 2 J Immunol 2 Leuk Lymphoma 1 Leuk Res 9 Leukemia 1 Oncol Rep 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Hematol

1. DIERKS F, Paulsen FO, Lehmberg K, Rosenwald A, et al
   Simultaneous onset of familial hemophagocytic lymphohistiocytosis and T-cell large granular lymphocytic leukemia in an adult.
   Ann Hematol. 2026;105:334.
   PubMed         Abstract available
   
   
2. ARORA K, Chowdhary R, Shenoy A, Kapadia C, et al
   Acute myeloid leukemia and gut microbiome: bidirectional effects and opportunities for intervention.
   Ann Hematol. 2026 Jul 15. doi: 10.1007/s00277-026-07176.
   PubMed         Abstract available
   
   
3. CHEN X, Gao L, Zhang Y, Hu Y, et al
   The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia.
   Ann Hematol. 2026 Jul 13. doi: 10.1007/s00277-026-07164.
   PubMed         Abstract available
   
   
4. LING W, Wu P, Wu S, Luo C, et al
   MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia.
   Ann Hematol. 2026 Jul 13. doi: 10.1007/s00277-026-07117.
   PubMed         Abstract available
   
   
5. MIHALYOVA J, Panovska A, Simkovic M, Smolej L, et al
   Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.
   Ann Hematol. 2026;105:326.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

6. OKUDA Y, Watanabe-Takahashi M, Nishikawa K
   Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation.
   Biochem Biophys Res Commun. 2026;829:154168.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

7. CHEN X, Guo C, Tu Y, Wei X, et al
   Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia.
   Biochem Pharmacol. 2026 Jul 11:118253. doi: 10.1016/j.bcp.2026.118253.
   PubMed         Abstract available
   
   

   
   Blood

8. MIMURA K, Kaino A, Ochi Y, Chang YH, et al
   BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.
   Blood. 2026;148:335-347.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. ORAL K, Uysal A
   Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience.
   BMC Cancer. 2026 Jul 16. doi: 10.1186/s12885-026-16560.
   PubMed         Abstract available
   
   

   
   Bone Marrow Transplant

10. WANG M, Luo J, Blaise D, Devillier R, et al
    Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes.
    Bone Marrow Transplant. 2026 May 8. doi: 10.1038/s41409-026-02872.
    PubMed         Abstract available
    
    
11. SILVA J, Galimard JE, Dalle JH, Locatelli F, et al
    The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT.
    Bone Marrow Transplant. 2026;61:891-898.
    PubMed         Abstract available
    
    
12. NAGLER A, Esteve J, Galimard JE, Wu D, et al
    Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.
    Bone Marrow Transplant. 2026 Jul 13. doi: 10.1038/s41409-026-02970.
    PubMed         Abstract available
    
    
13. CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al
    Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.
    Bone Marrow Transplant. 2026 Jul 16. doi: 10.1038/s41409-026-02975.
    PubMed        
    
    
14. MAFFINI E, Ngoya M, Houhou M, Benakli M, et al
    Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blo
    Bone Marrow Transplant. 2026 Jul 17. doi: 10.1038/s41409-026-02991.
    PubMed         Abstract available
    
    

    
    Br J Cancer

15. HOUMERA N, Genestier L, Huet S
    Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology.
    Br J Cancer. 2026;135:336-348.
    PubMed         Abstract available
    
    

    
    Cancer

16. MUSTAFA ALI MK, Zabor EC, Abdurakhmanov K, Zureigat H, et al
    Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.
    Cancer. 2026;132:e70524.
    PubMed         Abstract available
    
    

    
    Cancer Lett

17. SUN Y, Liu J, Chen J, Xuan L, et al
    Impact of Concurrent Genetic Alterations on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Cancer Lett. 2026 Jul 10:218724. doi: 10.1016/j.canlet.2026.218724.
    PubMed         Abstract available
    
    

    
    Cancer Res

18. PASTRANA CC, Nonavinkere Srivatsan S, Alberti MO, Hossan T, et al
    Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage.
    Cancer Res. 2026;86:3537-3553.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

19. KJAER CW, Sorum ME, De Pietri S, Moser C, et al
    Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Jul 17. doi: 10.1111/ejh.70267.
    PubMed         Abstract available
    
    
20. WANG Y, Xiao R, Huang X, Xiao Y, et al
    Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.
    Eur J Haematol. 2026 Jul 13. doi: 10.1111/ejh.70264.
    PubMed         Abstract available
    
    
21. MOLICA S
    Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship Perspective.
    Eur J Haematol. 2026 Jul 12. doi: 10.1111/ejh.70265.
    PubMed         Abstract available
    
    

    
    Exp Hematol

22. HASANI R, Pourseif MM, Alizadeh E, Tohidkia MR, et al
    CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances.
    Exp Hematol. 2026;160:105444.
    PubMed         Abstract available
    
    
23. FAGNAN A
    From gamma to X: same destination but different journey?
    Exp Hematol. 2026;160:105445.
    PubMed         Abstract available
    
    
24. RAJHANSA S, Crump NT, Khoo HM, Dopico-Fernandez A, et al
    Inhibition of MLLT1 limits growth of KMT2A::AFF1 leukaemias without killing healthy haematopoietic stem cells.
    Exp Hematol. 2026 Jun 3:105458. doi: 10.1016/j.exphem.2026.105458.
    PubMed         Abstract available
    
    

    
    Int J Hematol

25. ABUMIYA M, Takahashi N
    Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia.
    Int J Hematol. 2026 Jul 14. doi: 10.1007/s12185-026-04254.
    PubMed         Abstract available
    
    
26. MATSUI H, Takizawa J, Kojima K, Tauchi T, et al
    Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".
    Int J Hematol. 2026 Jul 14. doi: 10.1007/s12185-026-04253.
    PubMed        
    
    

    
    J Clin Oncol

27. ALCAZER V, Dulucq S, Mosnier I, Chabane K, et al
    Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.
    J Clin Oncol. 2026;44:1992-2005.
    PubMed         Abstract available
    
    

    
    J Immunol

28. BATTISTONE B, Ghazaryan A, Tang WW, Agir ZB, et al
    T-cell miR-155 regulates the response to tumor-specific mRNA vaccines in a murine model of acute myeloid leukemia.
    J Immunol. 2026;215:vkag184.
    PubMed         Abstract available
    
    
29. BHUMBRA SA, Good R, Banerjee A, Hines T, et al
    A novel Vdelta1 engager targeting CD19 enhances human Vdelta1 gammadelta T cell responses against CLL and CD19+ hematological malignancies.
    J Immunol. 2026;215:vkag167.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

30. FEDOROV K, Naranjo M, Esplund J, Leidy S, et al
    FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.
    Leuk Lymphoma. 2026 Jul 15:1-5. doi: 10.1080/10428194.2026.2700469.
    PubMed        
    
    
31. MINA A, Xu Y, Kapustyan TA, Dhalla M, et al
    Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.
    Leuk Lymphoma. 2026 Jul 12:1-9. doi: 10.1080/10428194.2026.2691911.
    PubMed         Abstract available
    
    

    
    Leuk Res

32. AGARWAL A, Chohan S, Bharti D, Kumar M, et al
    Clinicopathological stratification of myeloid sarcoma: Differences between acute leukemia-associated, chronic myeloid neoplasm-associated, and de novo disease - A single-center study of 126 cases.
    Leuk Res. 2026;168:108281.
    PubMed         Abstract available
    
    

    
    Leukemia

33. TOPP MS, Shah BD, Jabbour E, Park JH, et al
    Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Jul 17. doi: 10.1038/s41375-026-03045.
    PubMed         Abstract available
    
    
34. CORTES JE, Rea D, Mauro MJ, Hochhaus A, et al
    Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.
    Leukemia. 2026 Jul 16. doi: 10.1038/s41375-026-02972.
    PubMed         Abstract available
    
    
35. ZHANG M, Fields S, Zhang Q, Ouyang Y, et al
    Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry.
    Leukemia. 2026 Jul 16. doi: 10.1038/s41375-026-03064.
    PubMed         Abstract available
    
    
36. AZEVEDO RS, Jabbour E, Jain N, Haddad FG, et al
    Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.
    Leukemia. 2026 Jul 16. doi: 10.1038/s41375-026-03056.
    PubMed         Abstract available
    
    
37. KTORIDOU-VALEN I, Lenartova A, Grondal SM, Wogsland CE, et al
    Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia.
    Leukemia. 2026 Jul 15. doi: 10.1038/s41375-026-03054.
    PubMed        
    
    
38. ZHANG M, Li Y, Zhang B, Cai C, et al
    EIF4A3-dependent nonsense-mediated decay buffers AML1-ETO9a dosage and modulates outcome in t(8;21) acute myeloid leukemia.
    Leukemia. 2026 Jul 14. doi: 10.1038/s41375-026-03051.
    PubMed         Abstract available
    
    
39. VAN DER WERF I, Jamieson CHM
    Cancer is an RNA disease: DNA is not destiny, RNA determines leukemia fate.
    Leukemia. 2026 Jul 13. doi: 10.1038/s41375-026-03041.
    PubMed        
    
    
40. HALPERN AB, Othus M, Percival MM, Ghiuzeli C, et al
    Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.
    Leukemia. 2026 Jul 13. doi: 10.1038/s41375-026-03044.
    PubMed         Abstract available
    
    
41. QUINLAN L, Yeung D, Heatley S, White D, et al
    Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.
    Leukemia. 2026 Jul 17. doi: 10.1038/s41375-026-03060.
    PubMed         Abstract available
    
    

    
    Oncol Rep

42. NAPOLITANO R, De Matteis S, Carloni S, Bruno S, et al
    [Retracted] Kevetrin induces apoptosis in TP53 wild?type and mutant acute myeloid leukemia cells.
    Oncol Rep. 2026;56:149.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

43. SAXENA K, Hung SH, Ryu E, Chiu Y, et al
    CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells.
    Proc Natl Acad Sci U S A. 2026;123:e2601232123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum